Back to Search
Start Over
One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment
- Source :
- Diabetes, Obesity and Metabolism. 14:1032-1039
- Publication Year :
- 2012
- Publisher :
- Wiley, 2012.
-
Abstract
- Aim Assess long-term safety and efficacy of the dipeptidlyl peptidase-4 (DPP-4) inhibitor vildagliptin in 369 patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal impairment (RI). Methods Double-blind, randomized, parallel-group, 52-week clinical trial comparing safety and efficacy of vildagliptin (50 mg qd, n = 216) and placebo (n = 153) added to ongoing stable antihyperglycaemic treatment, in patients with T2DM and moderate or severe (glomerular filtration rate [GFR] ≥30 to
- Subjects :
- medicine.medical_specialty
business.industry
Endocrinology, Diabetes and Metabolism
Renal function
Type 2 diabetes
Pharmacology
medicine.disease
Placebo
Gastroenterology
Discontinuation
law.invention
Endocrinology
Randomized controlled trial
law
Diabetes mellitus
Internal medicine
Internal Medicine
Medicine
Vildagliptin
business
Adverse effect
medicine.drug
Subjects
Details
- ISSN :
- 14628902
- Volume :
- 14
- Database :
- OpenAIRE
- Journal :
- Diabetes, Obesity and Metabolism
- Accession number :
- edsair.doi...........765a206cfee0fe5ce16c22540af7b7f0